Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL360799 | 0.89 | AAK1 (0.32) | HTR4 | |
| SCHEMBL10356505 | 0.83 | MEN1 (0.32) | — | |
| SCHEMBL10324589 | 0.80 | FFAR1 (0.31) | — | |
| SCHEMBL360236 | 0.79 | AAK1 (0.31) | — | |
| SCHEMBL10353664 | 0.77 | CYP3A4 (0.33) | — | |
| SCHEMBL10352854 | 0.71 | GBA1 (0.32) | — | |
| SCHEMBL10353540 | 0.71 | KCNH2 (0.31) | — | |
| SCHEMBL10352906 | 0.70 | CYP3A4 (0.31) | — | |
| SCHEMBL10353221 | 0.70 | PPARD (0.30) | — | |
| SCHEMBL10324606 | 0.69 | CYP19A1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637523-B2 | Compounds for the reduction of beta-amyloid production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-01-28 | — | — | US | disclosed |
| US-20120184565-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184565-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | APP, BACE1, IAPP | HTR4 3831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.